Minerva Neurosciences, Inc. (NERV) Stock
NMQ · NERV
3.66
Fundamentals
Market cap
$174.76M
Price / Earnings ratio
-0.4x
Price / Sales ratio
N/A
Price / Book ratio
-0.8x
Return on assets
-6.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Minerva Neurosciences, Inc.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
SectorHealthcare
IndustryBiotechnology
Employees7
CEODr. Remy Luthringer Ph.D.
IPO DateJun 26, 2014
HeadquartersBurlington, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Remy Luthringer Ph.D. | Executive Chairman, CEO & Member of Scientific Advisory Board | 1961 |
| Mr. Frederick W. Ahlholm CPA | Senior VP, CFO & Secretary | 1966 |
| Mr. Joseph Reilly | Senior VP & COO | 1975 |
| Mr. Anthony Aliquo | Chief Accounting Officer & Principal Accounting Officer | 1987 |
| Mr. William B. Boni | Vice President of Investor Relations & Corporate Communications | 1952 |
| Mr. James O'Connor | Chief Business Officer & General Counsel | 1974 |
| Prof. Michael Davidson M.D. | Member of Scientific Advisory Board & Chief Medical Officer | 1950 |
Fundamentals
Valuation
Market cap$174.76M
Price-to-sales ratioN/A
Price-to-book value-0.77
Price-earnings ratio-0.40
Return on Equity360.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-36.24
Income Statement
Average volume238,505
EBITDA$-415.07M
1 year high (52w)$12.46
1 year low (52w)$1.93
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



